China SFDA Calls For Release Of Materials To Ease Hemophilia Treatment Shortage (China)
This article was originally published in PharmAsia News
China's State FDA says it has asked four blood-products companies in the country to release the raw materials used to make the clotting factor VIII to help eliminate a shortage of the materials needed to treat hemophilia. The agency sent the firms a notice seeking cryoprecipitate, a frozen blood product produced from plasma, to make them available to the three companies that produce factor VIII. The shortage was caused in part to a 50 percent drop in the plasma supply last year. (Click here for more )
You may also be interested in...
FDA warning to "Genesis II Church of Health and Healing " wasn't its first to the organization about promoting a chlorine dioxide formulation, "Miracle Mineral Solution," as an unapproved new drug. 'Infowars' host Alex Jones also was warned about bogus COVID-19 claims.
The first major revision since 2007 notably provides a legal foundation for special approvals under a public health crisis.
Resolution Medical teamed up with Carbon to introduce more than one million 3D-printed nasal swabs a week to address the shortage for COVID-19 testing.